United States· US:71610-680_737c6102-3cac-4ef5-812b-13e0298c7210
Glipizide
A glipizide product containing glipizide, registered in United States by Aphena Pharma Solutions - Tennessee, LLC. The same ATC class is registered in 8 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Glipizide is registered in 8 of 19 countries.
Countries holding a registration under ATC A10BB07 (glipizide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Glipizide · ATC A10BB07
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Franceprice
- Italyprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of glipizide costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.056 in United States to $0.39 in France — a ×7.0 gap.
- United States: $0.056 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Glipizide · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- FR France$0.39
- IT Italy$0.32
- US United States$0.056 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- GLIPIZIDE
- Manufacturer
- Aphena Pharma Solutions - Tennessee, LLC
- Country
- United States (US)
- ATC code
- A10BB07
- ATC class
- Glipizide
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 12
- ndc11716106804545 TABLET in 1 BOTTLE (71610-680-45)
- ndc11716106806090 TABLET in 1 BOTTLE (71610-680-60)
- ndc117161068073135 TABLET in 1 BOTTLE (71610-680-73)
- ndc117161068080180 TABLET in 1 BOTTLE (71610-680-80)
- ndc117161068092270 TABLET in 1 BOTTLE (71610-680-92)
- ndc117161068098540 TABLET in 1 BOTTLE (71610-680-98)
- ndc1171610-680-45
- ndc1171610-680-60
- ndc1171610-680-73
- ndc1171610-680-80
- ndc1171610-680-92
- ndc1171610-680-98
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
745 interactions on record for glipizide.
Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glipizide · interactions on record
745 records
- 20 severe
- 448 moderate
- 51 minor
- 226 info
Most severe, free to view
- MiconazoleA07AC01severe
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glipizide in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomGlibenese 5mg tabletsDowelhurst Ltd
- FinlandGlibenesePfizer Oy
- CzechiaMINIDIABPfizer, spol. s r.o., Praha
- SpainMINODIAB 5 mg COMPRIMIDOSPfizer S.L.
- PolandGlipizide BPFarmaceutyczna Spółdzielnia Pracy GALENA
- FranceOZIDIA 10 mg, comprimé à libération prolongéePFIZER HOLDING FRANCE
- BelgiumGlibenese 5 mgPfizer
- ItalyMINIDIAB*30 cpr 5 mgPFIZER ITALIA Srl
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Czechia · Minidiab
- Spain · Minodiab
- France · Ozidia
- United Kingdom (Northern Ireland) · Minodiab
- Italy · Minidiab
- Poland · Glipizide Bp Galena
- Romania · Glucotrol Xl
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eb8a5042-12f0-49df-b9df-898eaf8bce1b GET /v1/drugs/eb8a5042-12f0-49df-b9df-898eaf8bce1b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "5",
"substance": "GLIPIZIDE",
"productndc": "71610-680",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA074497",
"marketing_category": "ANDA"
}See everything about glipizide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.